MG29 Nucleic Acid Compositions for Muscle Function Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective pharmaceutical modulators for muscle function, particularly in addressing muscle dysfunction and aging-related deficiencies, with existing approaches failing to adequately target the complex membrane structures and physiological processes in skeletal muscle.
Innovation Solution
Development of nucleic acids encoding MG29 and MG29 receptor polypeptides, along with associated methods and compositions, to modulate gene expression and protein activity, targeting the excitation-contraction coupling processes in muscle cells for therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmaceutical approaches are used to modulate muscle function, then general muscle therapy is provided, but they fail to adequately target complex membrane structures and physiological processes in skeletal muscle
Solution Approach 1:
The patent segments the muscle function modulation approach by developing separate nucleic acid compositions targeting specific physiological processes (excitation-contraction coupling, calcium handling) rather than using general muscle therapy. This allows precise targeting of membrane structures and specific protein functions within the complex muscle system.
Solution Approach 2:
The patent uses nucleic acids (DNA, RNA) as intermediary molecules to deliver genetic information that directs the production of specific proteins involved in muscle function. These nucleic acids act as mediators between external therapeutic intervention and the internal physiological processes of muscle cells, enabling targeted modulation of excitation-contraction coupling and calcium handling.
2Adaptability or versatility
If general muscle therapy approaches are used, then broad muscle support is provided, but they lack specificity for aging-related muscle dysfunction and disease
Solution Approach 1:
The patent applies local quality by designing nucleic acid compositions with specific sequences that target particular protein functions and physiological processes in muscle. The therapy is not uniformly applied to all muscle functions but is specifically directed at excitation-contraction coupling and calcium handling mechanisms, providing localized precision within the broader muscle system.
Solution Approach 2:
The patent changes the fundamental parameter of therapeutic intervention from protein-based drugs to nucleic acid-based genetic therapy. This parameter change enables greater specificity because nucleic acids can be designed to match exact target sequences in muscle cell genomes, allowing precise targeting of aging-related dysfunction and disease-specific pathways.
3Measurement precision
If nucleic acid compositions encoding MG29 are used to target specific muscle processes, then precision in modulating muscle function is improved, but complexity of the therapeutic approach increases
Solution Approach 1:
The patent uses copying by introducing exogenous nucleic acid sequences that are identical or highly similar to the target muscle cell sequences. The therapeutic nucleic acids copy the functional elements needed for proper muscle protein production, allowing the muscle cells to produce the correct proteins without requiring complex external delivery systems or mechanisms.
Data Source
AI summary
Disclosed herein are compositions and methods for treatment of muscle dysfunction (including sarcopenia) and other diseases involving skeletal muscle, including age-related muscle dysfunction. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorder, including those related to thr normal aging process. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with altered intracellular Ca2+ regulation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced.